Form 4: Cingulate Inc. Executive Stock Option Grant

Raul R. Silva, EVP and CSO of Cingulate Inc., was granted stock options for 3,885 shares of common stock.

Summary

• Raul R. Silva, Executive Vice President and Chief Strategy Officer (EVP and CSO) of Cingulate Inc., received a grant of stock options.
• The options are for 3,885 shares of Cingulate Inc. common stock.
• The exercise price for these options is $5.47 per share.
• The grant date for these options was June 30, 2026.
• These options are exercisable starting June 30, 2026, and expire on June 30, 2036.
• The options were granted under the terms of Dr. Silva's Employment Agreement, as amended.
• Raul Silva directly beneficially owns these 3,885 shares following the reported transaction.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It represents a standard executive compensation action and does not provide new financial or strategic information about the company's performance or outlook.

Positives

• Grant of stock options to a key executive (EVP and CSO) indicates a commitment to retaining and incentivizing leadership.
• The stock options have a long expiration date (10 years), providing a significant incentive period.
• The exercise price of $5.47 suggests the options were granted at or near the current market price, aligning executive interests with shareholder value.
• The options are exercisable immediately, allowing the executive to benefit from potential stock appreciation.

Negatives

• The filing does not provide information on the company's financial performance or overall business outlook, making it difficult to assess the intrinsic value of the options.
• No details are provided regarding the performance conditions, if any, attached to the vesting or exercise of these options.

Risks

• The value of the stock options is directly tied to the future performance of Cingulate Inc.'s stock price, which is subject to market volatility and company-specific risks.
• If the company's stock price does not appreciate significantly above the exercise price of $5.47, the options may not hold material value for the executive.
• The filing does not disclose any specific risks related to the grant of these options themselves.

Future Outlook

The filing itself does not contain forward-looking statements or guidance regarding the company's future financial performance. The grant of stock options is an incentive mechanism for management.

Management Comments

• The option was granted pursuant to the terms of Dr. Silva's Employment Agreement, as amended.

Industry Context

StockSavvy.ai notes that the granting of stock options to executive officers is a common practice in the biotechnology and pharmaceutical sectors, like Cingulate Inc., to align executive incentives with long-term shareholder value creation and to attract and retain key talent in a competitive industry.

Related Party Transactions

• The stock option grant to Raul R. Silva, EVP and CSO, was made pursuant to his Employment Agreement, as amended, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The grant of options dilutes existing share ownership slightly but is intended to incentivize management to increase shareholder value.
• Employees: May view this as a standard executive compensation practice, potentially impacting morale depending on overall company performance.
• Management: Raul R. Silva benefits from potential future appreciation of Cingulate Inc. stock.

Next Steps

• Raul R. Silva may exercise his stock options if the stock price exceeds $5.47 per share.
• The company may continue to grant stock options as part of its executive compensation strategy.

Key Dates

Keywords

Cingulate Inc., CING, Form 4, Stock Options, Executive Compensation, Insider Trading, SEC Filing, Raul R. Silva, EVP and CSO, Beneficial Ownership